Last reviewed · How we verify
Rivaroxaban, Dabigatran
These are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation.
These are direct oral anticoagulants that inhibit key clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | Rivaroxaban, Dabigatran |
|---|---|
| Also known as | Xarelto, Pradaxa |
| Sponsor | University Hospital, Grenoble |
| Drug class | Direct oral anticoagulant (DOAC) |
| Target | Factor Xa (rivaroxaban); Thrombin/Factor IIa (dabigatran) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban is a Factor Xa inhibitor that blocks the intrinsic and extrinsic coagulation pathways. Dabigatran is a direct thrombin inhibitor that prevents the conversion of fibrinogen to fibrin. Both drugs reduce thrombus formation and are used to prevent thromboembolism in various conditions.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Acute coronary syndrome (rivaroxaban)
Common side effects
- Bleeding (major and minor)
- Dyspepsia
- Gastrointestinal bleeding
- Anemia
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- Anticoagulation in Patients With Venous Thromboembolism and Cancer
- High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
- SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
- Monitoring of NOAC Therapy: Standardizing Reference Intervals
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |